Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology - Canada
doi 10.3747/co.v17i2.470
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Related search

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Sunitinib for Advanced Renal Cell Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Correlation of C-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib

Clinical Genitourinary Cancer
OncologyUrology
2017English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy

New England Journal of Medicine
Medicine
2016English

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial

Oncologist
Cancer ResearchMedicineOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy